Working Memory in Preclinical Alzheimer's Disease: a Neuropsychological and Neuroimaging Investigation
Working Memory in Preclinical Alzheimer's Disease: a Neuropsychological and Neuroimaging Investigation
批准号:
10022086
负责人:
Joshua Thomas Fuller
金额:
$3.56万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2022-08-31
关键词:
AdultAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease pathologyAlzheimer&aposs disease riskAmericanAmyloid beta-ProteinAreaBehaviorBehavioralBilateralBrainBrain PathologyBrain regionCognitionCognitiveCohort StudiesColombiaColombianCorpus striatum structureDNA Sequence AlterationDementiaDetectionDevelopmentDiagnosisDiagnosticDiseaseEarly DiagnosisEarly InterventionEducationElderlyEpisodic memoryExecutive DysfunctionExhibitsExperimental DesignsFailureFamily memberFunctional Magnetic Resonance ImagingGoalsImageImpaired cognitionImpairmentIndividualInferiorInvestigationMeasuresMedialMemory LossMemory impairmentMentorshipMethodsMolecularMutationNeurobehavioral ManifestationsNeurodegenerative DisordersNeuropsychological TestsNeuropsychologyParietalParticipantPathogenesisPathologicPatternPerformancePharmaceutical PreparationsPittsburgh Compound-BPopulationPositron-Emission TomographyReaction TimeResearchResearch PersonnelRestRiskSamplingShort-Term MemoryStimulusTemporal LobeTestingTimeTrainingaging brainbasebehavior measurementcareercohortdisorder riskearly onseteffective therapyepisodic memory impairmentexecutive functionexperiencefrontierhigh riskinterestkindredmiddle agemolecular markermutation carrierneural correlateneurocognitive disorderneuroimagingnovelnovel strategiespre-clinicalpreclinical studypresenilin-1public health prioritiespublic health relevancerecruitskillssuccesstau Proteinsvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT
Alzheimer's disease (AD) is a debilitating neurocognitive disorder that is characterized by an insidious onset
and progressive course of memory decline and deficits in other cognitive domains, such as working memory.
Recently, AD research has focused on the preclinical detection and treatment of the disease, as earlier
detection and intervention may allow us to halt or slow AD pathogenesis. Previous research has identified
working memory difficulties in early symptomatic AD, suggesting that changes in this cognitive domain may
precede or co-occur with episodic memory impairment. Using resting and task-based activation and
connectivity on functional magnetic resonance imaging (fMRI) is a novel way to characterize the brain markers
and mechanisms that underpin working memory performance in preclinical AD. Neuropsychological measures
of working memory may reveal only subtle behavioral differences between individuals with preclinical AD and
healthy adults, but task and resting fMRI activation and connectivity in working-memory related networks may
be able to identify aberrant patterns that distinguish individuals at risk for AD. It is possible that network
disruption in working memory-related areas may also moderate the observed relation between AD brain
pathology (cortical amyloid-beta and medial temporal lobe tau) and episodic memory performance in the
preclinical stage of AD. This project will investigate (1) working memory-related task fMRI activation and
connectivity in preclinical ADAD; (2) the relation between working memory, episodic memory, and AD brain
pathology in preclinical ADAD and sporadic AD; and (3) resting-state brain network integrity in working
memory-related networks and its relations to AD brain pathology in preclinical sporadic AD and preclinical
autosomal dominant Alzheimer's disease (ADAD). Aim 1 will draw on young, cognitively unimpaired mutation
carriers and non-carrier family members from the Colombian ADAD kindred; carriers of this mutation
(presenilin1 E280A) are virtually guaranteed to develop dementia due to AD by their late 40s. Aims 2 and 3 will
similarly recruit Colombian kindred carriers and non-carriers, as well as cognitively normal older adults at risk
for sporadic AD based on elevated molecular markers of AD pathology see on positron emission tomography
(PET) in the brain. Through this project the applicant will (1) gain expertise in imaging and neuropsychological
methods related to investigating the neural correlates of working memory in preclinical ADAD and preclinical
sporadic AD, (2) receive training and mentorship on experimental design pertaining to cognitive and imaging
research on neurodegenerative diseases, and (3) establish professional relationships with experienced
researchers and collaborators who will equip him with the skills to transition to career independence.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Working Memory in Preclinical Alzheimer's Disease: a Neuropsychological and Neuroimaging Investigation
-
批准号:10246432
-
项目类别:
-
资助金额:$3.65万
-
财政年份:2019
-
负责人:Joshua Thomas Fuller
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: